menu search

PYXS / Pyxis Oncology: Cashed Up And Entering The Clinic

Pyxis Oncology: Cashed Up And Entering The Clinic
PYXS has initiated dosing with PYX-201 in a phase 1 study, with preliminary results due in early 2024. PYXS expects to initiate dosing in a phase 1 study of PYX-106 in Q2'23, which could add additional readouts to the 2024 calendar. Read More
Posted: Mar 27 2023, 07:32
Author Name: Seeking Alpha
Views: 112516

PYXS News  

Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)

By Zacks Investment Research
August 21, 2023

Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)

Pyxis Oncology, Inc. (PYXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined more_horizontal

Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?

By Zacks Investment Research
July 17, 2023

Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?

Pyxis Oncology, Inc. (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. Thi more_horizontal

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

By Seeking Alpha
June 12, 2023

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors res more_horizontal

Pyxis (PYXS) Up on Advancing Cancer Therapy Candidates

By Zacks Investment Research
May 31, 2023

Pyxis (PYXS) Up on Advancing Cancer Therapy Candidates

Pyxis' (PYXS) shares rise as the company advances its phase I candidates, PYX-106 and PYX-201, for challenging cancer therapies. more_horizontal

Pyxis Oncology: Cashed Up And Entering The Clinic

By Seeking Alpha
March 27, 2023

Pyxis Oncology: Cashed Up And Entering The Clinic

PYXS has initiated dosing with PYX-201 in a phase 1 study, with preliminary results due in early 2024. PYXS expects to initiate dosing in a phase 1 st more_horizontal

Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference

By GlobeNewsWire
June 28, 2022

Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference

CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation the more_horizontal

Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022

By GlobeNewsWire
March 22, 2022

Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022

CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset, multi-modality company focused on developing more_horizontal


Search within

Pages Search Results: